Generic Drugs Market Size, Share and Growth

1. Patent Expiration of Branded Drugs Fueling Generic Drugs Market Expansion 1 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

2. The global generic drugs market generated a revenue of $278.4 billion in 2019, and it is predicted to advance at a CAGR of 10.0% between 2020 and 2030. Furthermore, the market will reach a value of $786.0 billion by 2030. The factors driving the expansion of the market are the surging geriatric population, soaring prevalence of patient expiration of branded drugs, increasing incidence of acute and chronic diseases, and mushrooming research and development (R&D) expenditure of pharma and biotech companies. Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/generic-drugs- market-outlook/report-sample The surging population of geriatric people is one of the major factors propelling the advancement of the generic drugs market. As per a report published by the World Health Organization (WHO), people nowadays are living longer and their life expectancy has increased significantly. This has subsequently caused a massive rise in the global geriatric population. As medical treatments with branded drugs are very expensive, patients are increasingly preferring low-cost generic drugs, thereby fueling the expansion of the market. Another major factor propelling the growth of the market is the patent expiration of several blockbuster drugs. For example, the patent protection of DULERA, which is sold by Merck Sharp & Dohme Corp., expired in December 2020. Similarly, the patent protection of FORADIL, which is a drug sold by Novartis AG, expired in November 2020. Additionally, pharma companies are recognizing that people are increasingly preferring low-cost generics over costly branded drugs. This is further boosting the popularity of generic drugs. Besides the aforementioned factors, the growing incidence of chronic diseases is also pushing up the demand for generic drugs around the world. As per the WHO, chronic diseases are responsible for the deaths of up to three quarters of the global population. Out of all the deaths caused because of chronic diseases, in developing nations, ischemic heart diseases are responsible for 71% of the deaths, while 70% and 75% of the deaths are caused because of diabetes and stroke, respectively. Depending on application, the generic drugs market is classified into infectious diseases, cardiological diseases, respiratory diseases, neurological diseases, metabolic diseases, genitourinary/hormonal diseases, and orthopedic diseases. Out of these, the infectious diseases category led the market between 2014 and 2019, because of the high incidence of infectious diseases all over the world. The market is also divided, on the basis of type, into super, simple, and biosimilars. Amongst these, the simple category dominated the market in the past. 2 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

3. This was because of the high public preference for these generics, on account of their lower risk and lower cost than the others. Globally, Asia-Pacific (APAC) generated the highest revenue in the generic drugs market in 2019, and this trend is expected to continue in the coming years. This is credited to the surging geriatric population, soaring healthcare expenditure, rising prevalence of chronic diseases, and increasing implementation of government initiatives for promoting the usage of generics in this region. Therefore, it can be safely said that the market will grow rapidly in the coming years, primarily because of the lower costs of generics than the branded drugs, the patent expiration of several branded drugs, rising incidence of acute and chronic diseases, and the surging geriatric population across the world. 3 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

4. Disclaimer: P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies or organizations. P&S Intelligence is not responsible for any incorrect data provided by the key industry players of the concerned domain. The information or analysis in P&S Intelligence publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication, but cannot be guaranteed. P&S Intelligence does not endorse any product, service, or vendor depicted in its research publications. All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected by copyright. Under no circumstance can these be reproduced in any form without prior written agreement of their owners. An order for market research report is intended for internal use of the company only and not for disclosure to third parties or any other publication in general. No service, report, or part thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd. Kindly write to: enquiry@psmarketresearch.com B-13, Sector – 2, Noida, U.P. – 201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 4 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved